

FINANCIAL RESULTS

SALES WORLDWIDE¹

+2.9%

ON COMPARABLE OPERATIONAL BASIS*

\$6.6BN

RAISED FULL-YEAR 2017 GUIDANCE

\$2.43 to \$2.53 Adjusted EPS, reflecting double-digit growth.²

BUSINESS SEGMENT SALES

DIAGNOSTICS



\$1.3BN

MEDICAL DEVICES



NUTRITION




ESTABLISHED PHARMACEUTICALS



BUSINESS HIGHLIGHTS

Medical Devices

Strong 2Q17 growth for:



STRUCTURAL HEART

NEUROMODULATION

NEUROMODULATION

becomes **NUMBER 1** for treating chronic pain through spinal stimulation

New Diabetes
Collaboration: **Abbott**and
bigfoot

Product Milestones

EUROPEAN LAUNCHES



Confirm RX™ Insertable Cardiac Monitor (ICM) helps physicians remotely diagnose and treat difficult to detect irregular heartbeats (cardiac arrhythmias).**



Alinity hq hematology system improves efficiencies for high-volume labs. It is the fifth new diagnostic system launched in Europe since November 2016.**

CANADIAN APPROVAL



FreeStyle® Libre, a revolutionary continuous glucose monitoring system for people with diabetes.**

SUBMITTED FOR FDA APPROVAL



MRI-conditional labeling for the **Quadra Assura**™ Cardiac Resynchronization Therapy Defibrillator (CRT-D) will allow heart failure patients to undergo full body MRI scans, if required.**

*Comparable operational results are non-GAAP and include the prior year results for St. Jude Medical, and exclude the impact of exchange and prior and current year results for divested businesses. For full financial data and reconciliation of non-GAAP measures, please see our press release dated July 20, 2017.

FORWARD-LOOKING STATEMENTS

Some statements in this news release may be forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. Abbott cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Economic, competitive, governmental, technological and other factors that may affect Abbott's operations are discussed in Item 1A, "Risk Factors" to our Annual Report on Securities and Exchange Commission Form 10-K for the year ended Dec. 31, 2016, and are incorporated by reference. Abbott undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.

^{**}Not available for sale in the United States.

¹Reported sales +24.4% ²Full-year 2017 GAAP EPS guidance of \$1.03 to \$1.13